- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketMarket MoversStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare Tata India Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.11 | 1.89 |
NAV | ₹29.90 | ₹39.37 |
Fund Started | 04 Dec 2015 | 25 Jun 2018 |
Fund Size | ₹1231.67 Cr | ₹5507.52 Cr |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.11
1.89
NAV
₹29.90
₹39.37
Fund Started
04 Dec 2015
25 Jun 2018
Fund Size
₹1231.67 Cr
₹5507.52 Cr
Exit Load
Exit load of 0.25% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 13.65% | 21.93% |
3 Year | 24.87% | 29.75% |
5 Year | 21.50% | 25.03% |
1 Year
13.65%
21.93%
3 Year
24.87%
29.75%
5 Year
21.50%
25.03%
Holding Analysis
Equity | 90.83% | 96.99% |
Cash | 9.17% | 3.01% |
Equity
90.83%
96.99%
Cash
9.17%
3.01%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.64% |
Apollo Hospitals Enterprise Ltd. | 6.22% |
Cipla Ltd. | 5.83% |
Aurobindo Pharma Ltd. | 5.73% |
Divi's Laboratories Ltd. | 5.63% |
Fortis Healthcare Ltd. | 4.90% |
Lupin Ltd. | 4.82% |
Aster DM Healthcare Ltd. | 4.35% |
Wockhardt Ltd. | 3.27% |
Dr. Reddy's Laboratories Ltd. | 3.16% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.66% |
Dr. Reddy's Laboratories Ltd. | 9.66% |
Divi's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 7.85% |
Aurobindo Pharma Ltd. | 6.34% |
Alkem Laboratories Ltd. | 4.12% |
Zydus Lifesciences Ltd. | 4.01% |
Lupin Ltd. | 3.98% |
Gland Pharma Ltd. | 3.95% |
Syngene International Ltd. | 2.46% |
Fund Manager
Name | Meeta Shetty | Dharmesh Kakkad |
Start Date | 09 Nov 2018 | 23 Feb 2021 |
Name
Meeta Shetty
Dharmesh Kakkad
Start Date
09 Nov 2018
23 Feb 2021
About Fund
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Dec 2015 | 25 Jun 2018 |
Description
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
04 Dec 2015
25 Jun 2018